Study Pilot – Hybrid EEG/fMRI Neurofeedback in Depressed Patients

Overview

Cognitive impairment is a common residual symptom after a depressive episode and expose patients to a risk of relapsing or therapeutic resistance.

Neurofeedback (using ElectroEncephaloGraphy – EEG or functional Magnetic Resonance Imaging – fMRI) allows patients to self-regulate their cerebral activity, which is supposedly provided through an intelligible and motivating feedback.

Recent results exhibited clinical improvement in depressed patients who underwent a fMRI neurofeedback protocol targeting the amygdala. Furthermore, prefrontal alpha activity was temporally correlated to variations of the BOLD signal in the amygdala. Simultaneous fMRI/EEG neurofeedback is hypothesized to potentialize its antidepressant effect.

Our objective will be to test this assumption by conducting a double-blind randomized trial, and to prove the superiority of bimodal fMRI/EEG neurofeedback over fMRI neurofeedback alone in depressed patients.

An original visual feedback will be provided and validated beforehand by a pilot study.

Full Title of Study: “Study Pilot – Hybrid EEG/fMRI Neurofeedback in Depressed Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2021

Interventions

  • Other: EEG/fMRI neurofeedback
    • EEG/fMRI neurofeedback

Arms, Groups and Cohorts

  • Experimental: EEG/fMRI neurofeedback
    • Healthy volunteers

Clinical Trial Outcome Measures

Primary Measures

  • EEG power in alpha band
    • Time Frame: day 1
    • Measurement by an enregistrement in EEG
  • Cerebral activation in fMRI
    • Time Frame: day 1
    • Measurement by an enregistrement in fMRI

Secondary Measures

  • Technology prone behaviour
    • Time Frame: day 1
    • Measurement by Locus of Control Related to Technology (LCRT) (Beier, 2004, French translation Chikhi, 2017) : Description : Subjective 5-point Likert scale. 8 questions. Self-report. Minimal score : 8 Maximal score: 40 Interpretation : Assessment of the affinity to technology (higher score – better handling). No cut-off.
  • Anxious personality traits
    • Time Frame: day 1
    • Measurement by State Trait Anxiety Inventory (STAI – Y) (Spielberger, 1983, French translation Spielberger 1993) Description : 4-point Likert scale. 40 questions. Self report. Two parts : State-anxiety (20 questions) and Trait-anxiety (20 questions) Minimal score : 20 Maximal score : 80 Interpretation : > 65 – very high anxiety, 56-65 – high, 46-55 – average, 36-45 – low, < 35 – very low
  • Mindfulness skills
    • Time Frame: day 1
    • Measurement by Five Facets Mindfulness Questionnaire (FFMQ) (Baer, 2006, French translation Heeren, 2011) Description : 5-point Likert scale. 39 questions. Self-report. Five facets : Observing, Describing, Acting with awareness, Non-judging of inner experience, Non-reactivity to inner experience Minimal score : 39 Maximal score : 195 Interpretation : Measure of the tendency to be mindful in daily life (higher score – mindful traits). No cut-off.

Participating in This Clinical Trial

Inclusion Criteria

1. Aged 18 to 65 years old

2. Signature of an informed consent after being given clear and loyal oral and written information

Exclusion Criteria

Related to the volunteer

1. Prior experience of a neurofeedback task

Related to the MRI

2. Implanted cardiac pacemaker of defibrillator

3. Brain aneurysm clip

4. Cochlear implant

5. Ocular on encephalic metallic foreign body

6. Endoprothesis implanted for less than 4 weeks and ostheosynthesis device implanted for less than 6 weeks.

7. Claustrophobia

Other criteria

8. Unstable hemodynamic status

9. Acute respiratory failure

10. Alteration of general state or continuous monitoring requirement

11. Other psychiatric condition (DSM-5) such as schizophrenia, substance abuseā€¦

12. Neurological condition or diagnosis of dementia in medical history

13. Undergoing treatment by benzodiazepines or anticonvulsants prescribed less than a month prior to inclusion

14. Undergoing treatment influencing the blood flow prescribed less than three weeks prior to inclusion

15. Protected person (adults legally protected (under judicial protection, guardianship or supervision), person deprived of their liberty, pregnant woman, lactating woman and minor)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Rennes University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jean-Marie Batail, Principal Investigator, CHU Rennes
  • Overall Contact(s)
    • Nicolas Mevel, 02 99 28 25 55, dri@chu-rennes.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.